# US 2003/0232889 A1 · N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232889 A1
- Document ID: US20030232889A1
- Status: Published application
- Kind: A1
- Application number: 10/349,826
- Filed: 2003-01-23
- Published: 2003-12-18
- Earliest claimed: 2002-01-23
- Assignees: Pfizer Inc.
- Inventors: Stephen Douglas Barrett; Michael David Kaufman; Gordon William Rewcastle; Julie Ann Spicer
- Web page: https://patentgrep.com/patent/US20030232889A1

## CPC

- C07C 259/10: having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions, and methods of use thereof.

## Claims

### Claim 1

A compound of Formula
42
wherein
W is
43
R2 is hydrogen, methyl, fluorine, or chlorine;
R3 is hydrogen or fluorine;
R4 is —CH2S(CH2)m(CH3), —C≡C(CH2)qNHCH3, —C≡C—CH2OCH3, (Z)—CHCHCH2OCH3, —(CH2)nCO2R6, —(CF2)pCF3, —CH2(CF2)qCF3, —(CH2)mCF(CF3)2, —CH(CF3)2, —CF2CF(CF3)2, —C(CF3)3, —C≡C(CH2)qN(CH3)2, (Z)—CHCH—(CH2)qNHCH3, or (Z)—CHCH—(CH2)qN(CH3)2, C(O)C1-3 alkyl, or C(O)NHCH3;
m is 0 to 1;
n is 0 to 2;
p is 1 to 5;
q is 1 to 2;
R5 is hydrogen, fluorine, bromine, or chlorine;
R6 is hydrogen, methyl or ethyl;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein W is
44

### Claim 3 (depends on 1)

The compound of claim 1 wherein W is
45

### Claim 4 (depends on 1)

The compound of claim 1 wherein W is
46

### Claim 5 (depends on 1)

The compound of claim 1 wherein W is
47

### Claim 6 (depends on 1)

The compound of claim 1 wherein R2 is hydrogen, fluorine, or chlorine.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R3 is fluorine.

### Claim 8 (depends on 1)

The compound of claim 1 wherein R4 is —(CH2)nCO2R6.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R4 is —C≡C—CH2OCH3.

### Claim 10 (depends on 1)

The compound of claim 1 wherein R4 is C(O)CH3.

### Claim 11 (depends on 1)

The compound of claim 1 wherein R5 is hydrogen.

### Claim 12

A compound of Formula
48
wherein
W is
49
R2 is hydrogen, fluorine, or chlorine;
R3 is fluorine;
R4 is —CH2S(CH2)m(CH3), —C≡C—CH2OCH3, (Z)—CHCHCH2OCH3, —(CH2)nCO2R6, —(CF2)pCF3, —CH2(CF2)qCF3, —(CH2)mCF(CF3)2, —CH(CF3)2, —CF2CF(CF3)2, —C(CF3)3, —(Z)—CHCH—(CH2)qNHCH3, or (Z)—CHCH—(CH2)qN(CH3)2, or C(O)CH3;
n is 0;
R5 is hydrogen;
R6 is hydrogen or methyl;
and pharmaceutically acceptable salts thereof.

### Claim 13

A compound of Formula
50
wherein
W is
51
R2 is hydrogen, fluorine, or chlorine;
R3 is fluorine;
R4 is —C≡C—CH2OCH3, —(CH2)nCO2R6 or C(O)CH3;
n is 0;
R5 is hydrogen;
R6 is hydrogen or methyl;
and pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method of treating a proliferative disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 16 (depends on 15)

A method of claim 15 wherein the proliferative disease is selected from the group consisting of cancer, restenosis, psoriasis, and atherosclerosis.

### Claim 17 (depends on 1)

A method of treating psoriasis in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 18 (depends on 1)

A method of treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 19 (depends on 18)

A method of claim 18 wherein the cancer is MEK-related.

### Claim 20 (depends on 18)

A method of claim 18 wherein the cancer is brain, breast, lung, ovarian, pancreatic, prostate, renal, or colorectal cancer.

### Claim 21 (depends on 1)

A method of treating osteoarthritis in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 22 (depends on 1)

A method of treating rheumatoid arthritis in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 23 (depends on 1)

A method of treating heart failure in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 1)

A method of treating chronic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the chronic pain is selected from the group consisting of neuropathic pain, idiopathic pain, and pain associated with chronic alcoholism, vitamin deficiency, uremia, and hypothyroidism.

### Claim 26 (depends on 24)

The method of claim 24, wherein the chronic pain is associated with inflammation.

### Claim 27 (depends on 24)

The method of claim 24, wherein the chronic pain is associated with arthritis.

### Claim 28 (depends on 24)

The method of claim 24, wherein the chronic pain is associated with post-operative pain.

### Claim 29 (depends on 1)

A method of treating neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 30 (depends on 29)

The method of claim 29, wherein the neuropathic pain is associated with a condition selected from the group consisting of inflammation, postoperative pain, phantom limb pain, burn pain, gout, trigeminal neuralgia, acute herpetic and postherpetic pain, causalgia, diabetic neuropathy, plexus avulsion, neuroma, vasculitis, viral infection, crush injury, constriction injury, tissue injury, limb amputation, arthritis pain, and nerve injury between the peripheral nervous system and the central nervous system.

### Claim 31 (depends on 1)

A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 in combination with radiation therapy.

### Claim 32 (depends on 1)

A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 in combination with at least one chemotherapeutic agent.

### Claim 33 (depends on 29)

A method of claim 29 wherein the chemotherapeutic agent is a mitotic inhibitor.

### Claim 34 (depends on 30)

A method of claim 30 wherein the mitotic inhibitor is selected from the group consisting of paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, and vinflunine.

### Claim 35

A compound which is selected from the group consisting of
Methyl 4-[[2,3-difluoro-6-[[(2-hydroxyethoxy)amino]carbonyl]-phenyl]amino]benzoate;
4-[[2,3-Difluoro-6-[[(2-hydroxyethoxy)amino]carbonyl]phenyl]-amino]benzoic acid;
3,4-Difluoro-2-[[2-fluoro-4-(3-methoxy-1-propynyl)phenyl]-amino]-N-(2-hydroxyethoxy)benzamide;
Methyl 4-(2,3-difluoro-6-{[(2-hydroxyethoxy)amino]carbonyl}anilino)-3-fluorobenzoate;
4-(2,3-Difluoro-6-{[(2-hydroxyethoxy)amino]carbonyl}anilino)-3-fluorobenzoic acid;
2-(4-Acetyl-2-chloro-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethoxy)-benzamide; and
2-{2-fluoro-4-[(methylamino)carbonyl]anilino}-3,4-difluoro-N-(2-hydroxyethoxy)benzamide.
